Nanotechnology-enabled topical delivery of therapeutics in chronic rhinosinusitis.
Andy Jian Kai ChuaValentina Di FrancescoDi HuangAnisha A D'SouzaBenjamin S BleierMansoor M AmijiPublished in: Nanomedicine (London, England) (2023)
Chronic rhinosinusitis (CRS) is a chronic inflammatory disease of the paranasal sinuses which represents a significant health burden due to its widespread prevalence and impact on patients' quality of life. As the molecular pathways driving and sustaining inflammation in CRS become better elucidated, the diversity of treatment options is likely to widen significantly. Nanotechnology offers several tools to enhance the effectiveness of topical therapies, which has been limited by factors such as poor drug retention, mucosal permeation and adhesion, removal by epithelial efflux pumps and the inability to effectively penetrate biofilms. In this review, we highlight the successful application of nanomedicine in the field of CRS therapeutics, discuss current limitations and propose opportunities for future work.
Keyphrases
- chronic rhinosinusitis
- end stage renal disease
- oxidative stress
- small molecule
- ejection fraction
- newly diagnosed
- healthcare
- randomized controlled trial
- public health
- risk factors
- mental health
- systematic review
- peritoneal dialysis
- emergency department
- climate change
- cancer therapy
- current status
- health information
- staphylococcus aureus
- patient reported outcomes
- drug induced
- social media
- biofilm formation
- cell migration
- health promotion
- drug delivery
- electronic health record